ClinicalTrials.gg
RecruitingNCT07483294CINEMAUpdated May 26, 2026

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

A Phase 4 interventional study of risperidone and aripiprazole in Psychosis; Acute, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 15 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Northwell Health · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2025, registered Mar 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
15 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies testing risperidone in Psychotic Disorders — 2 open to participants now, 2 under way, 1 of them phase 3. Risperidone · Psychotic Disorders.

Planned enrollment
24th of 62
120 · median 98
Started
2025
with 1 other
Phase 4
29 of 66
1 open now
Registered
66th of 66
by date
Lead sponsor
6 of 66
Northwell Health

Among the 66 studies testing risperidone in Psychotic Disorders, this one is the 24th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2025, is one of 29 in phase 4, and was the 66th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

2 of the 66 studies testing risperidone in Psychotic Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 15 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing risperidone in Psychotic Disorders, or all of them as a file.
02

Study summary

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

Read the detailed description

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

03

Conditions studied

  • Psychosis; Acute

Browse trials for

04

Who can participate

Ages eligible
15 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a first-episode psychotic disorder including: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder Not Otherwise Specified (NOS), bipolar disorder with psychosis, and major depressive disorder with psychosis;
  • Current positive symptoms rated > 3 (moderate) on one or more of the Brief Psychiatric Rating Scale (BPRS) psychosis items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content;
  • At early phase of illness as defined by having taken antipsychotic drugs for a cumulative lifetime period of 8 weeks or less;
  • Age 15 to 40;
  • Competent to sign .

Exclusion criteria

Exclusion Criteria:

  • Serious neurological or endocrine disorder or brain trauma;
  • Any medical condition which requires treatment with a medication with psychotropic effects;
  • Significant risk of suicidal or homicidal behavior;
  • Cognitive or language limitations, or any other factor that would preclude subjects providing ;
  • to antipsychotic monotherapy;
  • Contraindications to MR imaging (e.g. pacemaker);
  • Pregnancy by self report.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Drug

    Open label drugs

    Drug: risperidone · Drug: aripiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cerebellar-cortical functional connectivity

    To investigate the performance of cerebellar-cortical functional connectivity in prediction of antipsychotic response

    Time frame: July 2025 - December 2029

  2. Cerebellar-cortical structural connectivity

    To investigate the performance of cerebellar white matter microstructures in prediction of antipsychotic response

    Time frame: July 2025 - December 2029

Secondary outcomes

  1. Cerebellar structural-functional integration

    To investigate the performance of integrated structural and functional connectivity in prediction of antipsychotic response

    Time frame: July 2025 - December 2029

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.

Of 45 non-industry phase 4 interventional studies under Psychotic Disorders, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 71. This study's planned 49 months is below that.

Counting every sponsor, half of 51 studies reached it within 58 months; a quarter within 32 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 19, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Dec 1, 2029
CompletionEst.
Jun 1, 2030
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07483294
Lead sponsor
Northwell Health
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
Nov 1, 2025
Primary completion
Dec 1, 2029 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
May 26, 2026

Study contacts

Hengyi Cao
Contact
hcao2@northwell.edu
718-470-5913
Juan Gallego
Contact
jgallego@northwell.edu
718-470-4588

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risperidone · Aripiprazole

Start the discussion